Survival rates of adult patients with Hodgkin lymphoma who underwent ABVD versus escalated BEACOPP in a resource‐limited country: An observational study

• Published in: Cancer reports 2023-08, Vol.6 (8), p.e1839-n/a
• Main Authors: Suwanban, Tawatchai, Chamnanchanunt, Supat, Thungthong, Pravinwan, Nakhahes, Chajchawan, Iam‐arunthai, Kunapa, Akrawikrai, Tananchai, Bunworasate, Udomsak
• Format: Article
• Language: English
• Subjects: adult; advance‐stage cancer; Biopsy; Chemotherapy; Hodgkin disease; Hospitals; life expectancy; limited resource country; Lymphatic system; Lymphocytes; Lymphoma; Medical records; Observational studies; Original; Radiation therapy; Tomography; Ultrasonic imaging
• ISSN: 2573-8348; 2573-8348
• DOI: 10.1002/cnr2.1839

Background The survival rate of adult patients with Hodgkin lymphoma (HL) depends on the responses to standard chemotherapy, radiotherapy, or combined therapy. Resource‐limited countries face numerous obstacles in supporting patients with HL who undergo chemotherapy, especially in advanced stages. Aim To analyze the survival outcomes of adult patients with HL after combined‐modality treatment (CMT) with involved‐field or non‐involved‐field radiotherapy. Methods and Results We retrospectively reviewed the medical records of 90 adult patients with HL who received CMT at Rajavithi Hospital, Bangkok between 2007 and 2021. Patients with stage I‐IV disease received different therapies depending on their risk group. The risk groups were evaluated according to initial response, bulky disease, and B symptoms. Patients (n = 90) who underwent CMT were followed up for 34.7 months (range, 1–141 months). The median follow‐up periods of early and advanced‐stage patients were 53.1 months and 23.5 months, respectively. The estimated 5‐year overall survival (OS) and progression‐free survival (PFS) rates of patients with advanced‐stage diseases were 85% and 62%, respectively. There was a difference in the 3‐year overall survival among advance‐stage patients who underwent ABVD (94%) compared to those administered BEACOPPesc (50%), and the 3‐year PFS (84%) among patients who underwent ABVD was higher than that among those administered BEACOPPesc (66%). Radiotherapy increased toxicity but did not improve the survival rate. Conclusion Chemotherapy administered to patients with advanced‐stage adult HL was more effective than BEACOPPesc when ABVD was administered. Our findings are relevant for hospitals with limited resources.